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Vitamin Bs and the toxicity of l,l-dimethylhydrazine* 
(Received 23 February 1966; accepted 10 June 1966) 
IT IS well known that 1,1-dimethylhydrazine (UDMH) inhibits certain enzymatic reactions requiring 
vitamin BE as a cofactor,‘, 2 apparently through the formation of a UDMH-pyridoxal or pyridoxa 
phosphate hydrazone which depletes the tissues of vitamin B6. Other workers have demonstrate< 
that intraperitoneally administered pyridoxine (PY) protects rats from UDMH toxicity, while 
pyridoxal (PAL) and pyridoxal phosphate (PALP) do not. 2. 3 When PAL and PALP were injectec 
immediately after UDMH, convulsions and death occurred much sooner than with UDMH alone 
Similar findings with PAL4 and PALP3 have been reported for hydrazine and a number of substitute1 
hydrazines. 
In the present study, the Bs vitamers were injected intracerebrally into UDMH-treated rats tl 
circumvent the blood-brain barrier. On the basis of these findings, the protective effects of intra 
peritoneally injected vitamers then were re-examined. 
* This study was sponsored by the Commission on Environmental Hygiene of the Armed Force 
Epidemiological Board, and was supported in part by the Medical Research and Developmer 
Command, Office of the Surgeon General, Department of the Army of the United States. 
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MATERIALS AND METHODS 
Adult (250-350 g) male rats of the Sprague-Dawley (Rawley Farms) strain were used. The animals 
received Rockland rat and mouse chow and water ad libitum. 
UDMH-treated animals were given an LDIOO i.p. dose of 120 mg/kg. UDMH (Matheson, Coleman 
& Bell) was dissolved in 27 mM sodium bi~rbonate in 0.9% saline such that the final solution 
contained 50 mg UDMH/ml. The three vitamers used for intracerebral injections were dissolved in 
@97: saline. It was necessary to add a few drops of dilute NaOH to achieve complete solution of 
high concentrations of PALP. 
lntracerebral injections were carried out as follows. A small hole was drilled through the skull of 
anesthetized rats at a point 2 mm posterior to the coronal suture and 2 mm dorsal to the sagitta! 
suture. A microliter syringe with a 26-gauge needle inserted to a depth of 3 mm from the skull surface 
was used for the injections. The complete procedure required about 10 min, and recovery was rapid. 
Although the largest dose of Bs was injected in a volume of 30 ~1, most volumes were 15 ~1 or smaller. 
For each of the three Be vitamers, a wide range of dosages was administered intracerebrally to normal 
rats to determine the response to the compound, the minimum lethal dose, and the dose level below 
which no response occurred. The work was repeated in rats previously injected with UDMH. Bs 
vitamers were given intracerebrally just after the first convulsion, which occurred approximately 
90 nun after UDMH injection. The rats were observed for 6 hr after UDMH administration. Previous 
studies have shown that most deaths in UDMH-treated rats occur within this period.5 
A wide range of intraperitoneal dosages of PAL and PALP was then examined for their ability 
to protect rats from UDMH-induced convulsions and death. 
RESULTS 
In~racerebral studies. Intracerebral doses of 3-6 mg PY or 4 mg PAL produced convulsions and 
death in nearly all animals, whereas smaller doses were less toxic (Table I). PALP appeared more 
TAKE 1. EFFECT OF INTKACEREBRAL INJECTION OF PYRIWXINE (PY), PYRIDOXAL (PAL), AND PYRI- 
DOXAL PHOSPHATE (PALP) ON NORMAL AND VDMH-TREATED* RATS 
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* UDMH (120 mg/kg; i.p.) 90 min before Ba administration. 
t Convulsions : number convulsing/number treated. 
f Mortality: number dead/number treated. 
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toxic in normal rats than the other Bs vitamer, since 1 mg given intracerebrally resulted in death of all 
animals tested. Doses ranging from 0.05 to 1 mg PY prevented death in 22 of 23 rats which had 
received an ordinarily lethal dose of UDMH (P < 0.001). Convulsions were observed, however, in 
UDMH-treated rats receiving more than 1 mg or less than 0.5 mg of PY. 
PAL in doses ranging from 0.25 to 1.00 mg per rat prevented convulsions and fatalities in all 17 
rats receiving UDMH (P < 0.001). Dosages of PAL greater or less than these amounts were not 
completely effective in preventing UDMH toxicity. 
Doses of PALP ranging from 0.03 to 0.17 mg protected 18 of 23 rats from the lethal effects of 
UDMH (P < 0031), but no dose was found to be completely effective in preventing convulsions. 
Intraperitoneal studies. Doses of 100 mg/PY, PAL, or PALP per kg had no apparent effect on 
normal rats (Table 2). Ten of twelve rats given 25-100 mg PAL/kg 90 min after UDMH convulsed, 
but only three died. Rats given 5 or IO mg PAL/kg appeared to be completely protected from the 
toxic effects of UDMH. 
Although 5-10 mg PALPjkg partially protected against UDMH toxicity, no dosage of PALP 
TABLE 2. EFFECT OF INTRAPERITONEAL INJECTION OF PYRIDOXAL (PAL), PYRIDOXAL PHOSPHATE (PALP), 
OR PYRIDOXINE (PY) ON NORMAL AND UDMH-TREATED RATS* 
Bo Vitamer Dose 
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* See footnotes to Table 1. 
t First dose of PALP given 90 min after UDMH and second dose given after 
an additional 45 min. 
was found that would completely prevent convulsions in UDMH-treated animals. Attempts to 
protect UDMH-injected animals by giving two doses of 2 mg PALP/kg 45 min apart were only 
partially effective, and two 5 mg/kg doses prevented fatalities, but some animals convulsed. 
UDMH-treated animals were completely protected by lo-50 mg PYlkg (Table 2). Three of six 
rats treated with 5 mg PY/kg had single convulsions. 
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Since appropriate doses of PY, PAL, or PALP protected against UDMH toxicity when given 
I.5 hr after UDMH. the effect of various doses of each vitamer when given simultaneously with 
UDMH was examined (Table 3). Animals injected with UDMH and PAL (30-100 mg/kg) or PALP 
(SO-60 mg/kg) convulsed and died within 1 hr. All rats given 10 mg PAL/kg convulsed, but there were 
no deaths. Of six rats treated with 10 mg PALP/kg, five convulsed and one died. Ten to 50 mg 
PY/kg protected against UDMH toxicity, although one rat convulsed. Aft UDMH rats treated with 
S mg PYjkg convulsed and two of six died. 
TABLE 3. EFFECT OF SWJLTANEOUS INTRAPERITONEAL INJEcrIoN OF PYRIDOXAL (PAL), PYRIDOXAL 
I'HOspHATE(PALP),OR PYRIDOXlNE(PY) WITH UDMH* 
BG Warner Dose 












5 616 (W . (33) 
* See footnotes to Table 1. 
DISCUSSION AND CONCLUSIONS 
This study demonstrates that appropriate intracerebral or intraperitoneal doses of PAL, PALP, 
and PY are effective antidotes against UDMH. The inabiI~ty of previous workers22 d to demonstrate 
a protective effect of PAL and PALP appears to be related to the dosage used. Doses above or below 
rather closely defined limits were not effective in protecting against UDMH toxicity. In addition, 
treatment was more effective when delayed until the onset of severe symptoms. Several factors may 
account for this finding. The excretion of UDMH begins rather rapidly,6e 7 thus a smaller amount 
of UDMH would be available for the formation of toxic hydrazone with injected Be. Injection of 
the vitamer nearer to the time of tissue depletion of Ba would make high levels of the coenzyme avail- 
able to the cell at the most critical time. Injected PAL or PALP may be converted to UDMH- 
hydrazones in situ, leaving little coenzyme available for metabolic functions at distant sites. In 
contrast, the injection of PY provides a 3s reservoir which does not form a UDMH hydrazone, 
thereby providing for its conversion to active coenzyme at the site of enzymatic activity. 
It becomes apparent that successful treatment of UDMH toxicity with PAL or PALP presents a 
rather difficult problem of balance among the effects of the Bti vitamer, the UDMH-hydrazone, and 
UDMH. Thus pyridoxine, which is effective over a wide dosage range, remains the vitamer of choice 
in treating UDMH toxicity. 
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Studies of the inhibition of lipolytic enzymes--III. 
The inhibition of a Tween hydrolase from rat adipose tissue in vitro and in vivo by 
n-butyl carbamic acid methyl ester, U-14641 
(Received 5 May 1966; accepted 13 June 1966) 
n-BUTYL carbamic acid methyl ester (BCME) has been demonstrated to be a potent species-specific 
inhibitor of canine liver and kidney 1ipase.l The isolation and extensive purification of a Tween 
hydrolase from rat adipose tissue has also been reported.2 The experiments reported herein demon- 
strate that BCME is an inhibitor, both in vitro and in vivo, of Tween hydrolase from rat adipose tissue. 
METHODS 
For the kinetic experiments, Tween hydrolase was highly purified by the procedure hitherto 
reported.2 Enzyme activity in uivo was determined in male Sprague-Dawley rats weighing 250-300 g, 
and fed Purina lab chow ad libitum. BCME was made up in water at a concentration of 0.1 M and 
was administered i.v. into the tail veins. The rats were killed by decapitation, and the epididymal and 
perirenal fat pads were quickly excised and chilled in cold water. The water was then decanted and 
the pads, blotted dry and weighed, were homogenized in a chilled Waring Blendor for 1 min at top 
speed in 2 volumes (v/w) of cold water. The resulting homogenate was centrifuged at 5000 g for 
10 min at 0”. The supernatant fluid was filtered through cheesecloth to remove particles of fat, and 
the Tween hydrolase activity was assayed as follows. To 15-ml conical centrifuge tubes was added 
500 pmoles ammonium chloride buffer, pH 8.35; 0.25 ml adipose tissue extract prepared as des- 
cribed; 25 pmoles Tween 20 (Atlas Chemical Industries), and water to a tinal volume of 2 ml. 
Incubations were for 10 min at 38”. 
In the kinetic experiments, because small volumes of highly purified enzyme (30 units*/tube) were 
needed, the final volume of the incubation mixture was reduced to 1 ml and 250 pmoles of buffer 
was used, along with varying amounts of substrate. All components were added except the substrate, 
and a 3-min preincubation period was employed to ensure establishment of steady-state conditions 
between enzyme and inhibitor. The tubes were then removed from the water bath, chilled, and the 
Tween substrate added, following which the tubes were again incubated for 10 min at 38”. At this 
time the tubes were again removed from the bath, chilled in ice slush, and the reaction stopped by 
addition of 7.5 ml of a solvent mixture of 4: 1 :O.l isopropanol: heptane: 1 N HzS04 per ml incubation 
medium. Fatty acids were extracted and titrated by the method of Ko and Royer.t Appropriate 
enzyme and substrate blanks were carried in every experiment to correct for endogenous fatty acid. 
RESULTS AND DISCUSSION 
Under the described conditions for kinetic experiments, with 10 pmoles Tween substrate, BCME 
was found to inhibit the enzyme 93 per cent at a concentration of 5 v 10m3 M, 85 per cent at 5 ,X 
1O-4 M, and 56 per cent at 5 x 10e5 M. 
* According to international usage, 1 unit of enzyme is that amount of enzyme required to liberate 
1 pmole fatty acid/hr under specified conditions of assay. 
t Unpublished. 
